Fat profits: should you invest in weight-loss drugs?

The latest weight-loss treatments could transform public health and the world economy. Should you invest?

Weight-loss injections
(Image credit: Douglas Sacha via Getty Images)

When considering the top stocks, funds and trusts to invest in, are the pharmaceutical and biotech companies behind weight-loss drugs worth a look?

“In 2021, Lisa Chen, a software engineer, started a new weight-loss medication,” says Todd Gagne on his Substack page Wildfire Labs. Six months later, she had stopped buying a daily muffin. Then she cancelled her beer-of-the-month subscription and kicked her late-night takeaway habit. By 2023, her grocery bill had dropped 40%, her alcohol spending 85%, and her Amazon impulse purchases 60%. “Our economy is built on impulses,” Gagne writes. “What happens when a weekly injection regulates those impulses?”

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up
Katie Williams
Staff Writer

Katie has a background in investment writing and is interested in everything to do with personal finance, politics, and investing. She enjoys translating complex topics into easy-to-understand stories to help people make the most of their money.

Katie believes investing shouldn’t be complicated, and that demystifying it can help normal people improve their lives.

Before joining the MoneyWeek team, Katie worked as an investment writer at Invesco, a global asset management firm. She joined the company as a graduate in 2019. While there, she wrote about the global economy, bond markets, alternative investments and UK equities.

Katie loves writing and studied English at the University of Cambridge. Outside of work, she enjoys going to the theatre, reading novels, travelling and trying new restaurants with friends.